Status:
COMPLETED
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Johns Hopkins Bloomberg School of Public Health
Conditions:
Influenza
Virus Diseases
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it. Other r...
Detailed Description
It is very likely that during an influenza pandemic, intravenous zanamivir will be used in combination with oseltamivir. Although the potential for a drug interaction between the two drugs is very low...
Eligibility Criteria
Inclusion
- Good general health
- Body mass index between 17 - 32 kg/m\^2
- Body weight of at least 37 kg
- Able to read, comprehend, and write at a sufficient level to complete study-related materials
- Normal ECG with QTC less than 450 msec as judged by cardiologist
- Willing and ability to comply with the study protocol for the duration of the trial
Exclusion
- History of cardiac disease or abnormality. More information on this criterion can be found in the protocol.
- Family history of sudden cardiac death
- HIV-infected
- Hepatitis C virus infected
- Positive for hepatitis B surface antigen (HBsAg)
- History of renal disease, hepatic disease, and/or cholecystectomy
- Evidence of active substance abuse
- History of alcohol or substance abuse or dependence within 6 months prior to study entry. More information on this criterion can be found in the protocol.
- Use of prescription or non-prescription drugs, except paracetamol, at doses of up to 2 g/day. More information on this criterion can be found in the protocol.
- Use of FluMist, inactivated influenza vaccine, or any other anti-influenza antiviral medications within 14 days prior to study entry
- Participated in a clinical trial and received a drug or new chemical entity within 30 days or five half-lives prior to study entry.
- Unwilling to abstain from ingesting alcohol within 48 hours prior to study entry until collection of the final pharmacokinetic sample during each period
- Donated blood to the extent that participation in this study would result in excess of 300 mL donated within a 30 day period
- History of allergy to the study drug or drugs of this class. More information on this criterion can be found in the protocol.
- Unstable medical condition that, in the opinion of the investigator, would interfere with the study
- Anyone that, in the opinion of the investigator, has a risk of non-compliance with study procedures
- AST or ALN of at least 1.5 ULN
- Certain abnormal laboratory values
- Agree to use effective methods of birth control. More information on this criterion can be found in the protocol.
- Pregnant or breastfeeding
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00921726
Start Date
July 1 2009
End Date
October 1 2009
Last Update
March 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mathidol University
Salaya, Thailand, 73170